Posted On: 10/31/2015 3:24:10 PM
Post# of 30066
I posted the message below a few weeks ago. I believe what you say is true if you only had one indication. The Biogen example below shows what happens when a company has "Multiple Shots on Goal" (slide 7). They have similar collaborations.
Quote:
A common myth is you can't partner until after phase 2 data. I posted about AGTC. It's solely focused on ophthalmology development programs and has proof-of-concept data in multiple indications. AMBS has two ODD in ophthalmology, many areas outside of ophthalmology for MANF, ESS, Elto, Dx...
If you view the Sep 18, 2015 investor presentation here, you can get the whole story, timeline, royalties, etc. ir.agtc.com/events.cfm
Investor Presentation
http://files.shareholder.com/downloads/AMDA-2...tation.pdf
(0)
(0)
